Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers...Wikipedia

Manufacturer's Website: Lynparza

Average retail cost: $13,400/month

Rucaparib (brand name Rubraca) is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). In December 2016, the U.S. FDA granted an accelerated approval for use in cases of pretreated advanced ovarian cancer...Wikipedia

Manufacturer's Website: Rubraca

Average retail cost: $14,600/month

Niraparib (trade name Zejula) is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer...Wikipedia

Manufacturer's Website: Zejula

Average retail cost: $15,400/month